Overview
Gene therapy firm's Q2 net loss widened to $11.8 mln
Company's R&D expenses in Q2 were $5.8 mln, consistent with last year
Company plans FDA meeting mid-2026 for BB-301 pivotal study design
Outlook
Company plans FDA meeting to finalize BB-301 pivotal study design mid-2026
Benitec expects interim clinical results update for Cohort 2 in mid-2026
Company received Fast Track Designation for BB-301 from FDA
Result Drivers
DURABLE RESPONSE - All four patients in Cohort 1 of BB-301 study showed durable response at 12-month follow-up
IMPROVEMENTS AT 24-MONTH - Patient 1 of Cohort 1 showed further improvements in symptoms at 24-month follow-up
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 EPS
-$0.26
Q2 Net Income
-$11.80 mln
Q2 Operating Income
-$13.40 mln
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Benitec Biopharma Inc is $24.00, about 106% above its February 11 closing price of $11.65
Press Release: ID:nGNXYbrZ1
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
